Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 2.29M -88.6% |
| Revenue (ttm) | 20.90M +45.2% |
| Net Income | -25.46M |
| EPS | -1.83 |
| Shares Out | 20.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 741,948 |
| Open | 0.1150 |
| Previous Close | 0.1206 |
| Day's Range | 0.1110 - 0.1191 |
| 52-Week Range | 0.1110 - 2.7200 |
| Beta | 6.30 |
| Analysts | Buy |
| Price Target | 1.93 (+1,591.56%) |
| Est. Earnings | Nov 18, 2026 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its a... [Read more]
Financial Performance
In 2025, Vivos Therapeutics's revenue was $17.44 million, an increase of 16.05% compared to the previous year's $15.03 million. Losses were -$21.17 million, 90.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price target is $1.93, which is an increase of 1,591.56% from the latest price.
News
Vivos Therapeutics Proxy statement: Proxy filing
Vivos Therapeutics filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
Vivos Therapeutics regains Nasdaq stockholders’ equity compliance
Vivos Therapeutics (VVOS) announced receipt of a letter from the Listing Qualifications staff of Nasdaq on October 20 stating that the company currently complies with Listing Rule 5550(b)(1), requirin...
Vivos Therapeutics Proxy statement: Proxy filing
Vivos Therapeutics filed a proxy statement on October 21, 2026, providing details for shareholder voting and corporate governance matters.
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and comme...
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Th...
Vivos Therapeutics Proxy statement: Proxy filing
Vivos Therapeutics filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Vivos Therapeutics to acquire 11% stake in SOD Sciences for $12M in preferred
Vivos Therapeutics (VVOS) announced that it has entered into a definitive mutual stock purchase and asset exchange agreement to acquire an 11% fully diluted equity interest in SOD Sciences and…
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Transaction Expected to Increase Stockholders' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances Transaction Expected to Increase Stockholders' Equity; Opens Potential C...
Vivos Therapeutics reports progress in material cost reductions, revenue growth
Vivos Therapeutics (VVOS) announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6M annually, beginning in Q4 2026. Parts of the plan have…
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos Management is Executing on Plan to Immediately Redu...
Vivos Therapeutics Announces Material Debt Reduction
LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and comm...
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on ...
Vivos Therapeutics, SPCVA to launch regional sleep testing and treatment center
Vivos Therapeutics (VVOS) announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, or SPCVA, to support the establishment and operation o...
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing a...
Vivos Therapeutics reports new patient referrals at Nevada Sleep & Airway
Vivos Therapeutics (VVOS) announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior…
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing a...
Vivos Therapeutics opens sleep testing, treatment facility in Nevada
Vivos Therapeutics (VVOS) announced the official Grand Opening of its latest state-of-the-art diagnostic, testing, and treatment location in Henderson, Nevada. The company expects this new full-servic...
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics Earnings Call Transcript: Q2 2026
Revenue rose 35% year-over-year in Q2 2026, driven by service growth from SCN and new treatment centers, while recurring revenue initiatives and clinical expansions are expected to accelerate growth into 2027. Cash constraints and Nasdaq compliance remain key risks.
Vivos Therapeutics Quarterly report: Q2 2026
Vivos Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Vivos Therapeutics Earnings release: Q2 2026
Vivos Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Au...
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing ...
Vivos Therapeutics expands strategic engagement with Greenway Health
Vivos Therapeutics (VVOS) announced an expanded strategic engagement with Greenway Health to deploy Greenway’s new AI-by-design Novare platform across Vivos’ growing clinical operations. Program imple...
Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1...